Battling Arthritis

Methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) commonly prescribed to RA (rheumatoid arthritis patients).

Now, according to Australian researchers, increased risk of melanoma (including other malignancies) have in found in RA patients receiving MTX for treatment.

RA patients exposed to MTX were found to have an estimated 50 percent excess risk of developing cancer in any form. The risk of non-Hodgkin’s lymphoma was more than 5 times higher in RA patients than in the general population. RA patients also had a 3-fold increased risk of melanoma and almost a 3-fold increased risk of lung cancer.

More →

Share This

Modern Biosciences plc has signed an exclusive worldwide license agreement with the University of Aberdeen in order to further develop new treatments for rheumatoid arthritis (RA) and to put into trials the new RA drugs that Aberdeen has discovered but haven’t been tested yet.

Rheumatoid arthritis is a debilitating disease that causes inflammation of the joints which affects some 1% of the worldwide population (or approximately 165 million people. More →

Share This